{"ModuleTitle": "Company Description", "CompanyName": "Satsuma Pharmaceuticals, Inc.", "Symbol": "STSA", "Address": "400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO, California, 64080, United States of America", "Phone": "415-505-0809", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a clinical-stage biopharmaceutical company developing a novel therapeutic\r\nproduct for the acute treatment of migraine. Our product candidate, STS101, is a\r\ndrug-device combination of a proprietary dry-powder formulation of\r\ndihydroergotamine mesylate, or DHE, which can be quickly and easily\r\nself-administered with a proprietary pre-filled, single-use, nasal delivery\r\ndevice. DHE products have long been recommended as a first-line therapeutic\r\noption for the acute treatment of migraine and have significant advantages over\r\nother therapeutics for many patients. However, broad use has been limited by\r\ninvasive and burdensome administration and/or sub-optimal clinical performance\r\nof available injectable and liquid nasal spray products. STS101 is specifically\r\ndesigned to deliver the clinical advantages of DHE while overcoming these\r\nshortcomings.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f10%2f0001564590-20-009753.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Detlef F. Albrecht", "title": "Chief Medical Officer"}, {"name": "John A. Kollins", "title": "President, Chief Executive Officer & Director"}, {"name": "Mic Iwashima", "title": "Head-Operations & Vice President"}, {"name": "Thomas P. O'Neil", "title": "Chief Financial & Accounting Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}